Abstract
β2-Glycoprotein I (β2-GPI) is a major antigen for anticardiolipin antibodies (aCL) induced in patients with antiphospholipid syndrome and their antigenic epitopes are cryptic. The epitopes appear on the surface of β2-GPI molecule only when β2-GPI interacts with lipid membranes containing negatively charged phospholipids or polyoxygenated polystyrene surface. Our data also indicated that CuSO4-oxidized low density lipoproteins (oxLDL) are subsequently targeted by β2-GPI and aCL; however, malonedialdehyde (MDA)-modified LDL were recognized neither by β2-GPI nor aCL. β2-GPI binding to LDL was rapidly increased by incubation with CuSO4. Oxidation of lipoproteins was accompanied with the increment of thiobarbituric acid-reactive substances (TBARS) and denature of apolipoprotein. Ligands on LDL for β2-GPI seemed to be intermediate oxidative derivatives which were extractable into the chloroform phase by Bligh and Dyer's extraction, but not MDA. Further, immune responses against β2-GPI, as an anti-atherogenic protein, were demonstrated to induce atherogenic effect in in vitro oxLDL uptake by macrophages.
Original language | English |
---|---|
Pages (from-to) | S135-S139 |
Journal | Lupus |
Volume | 7 |
Issue number | SUPPL. 2 |
DOIs | |
Publication status | Published - 1998 |
Keywords
- Anticardiolipin antibodies
- Atherosclerosis
- Foam cell
- Oxidized LDL
- β-glycoprotein I
ASJC Scopus subject areas
- Rheumatology